This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
A China-developed KRAS inhibitor led to objective responses in half of patients with previously treated KRAS-mutant non-small cell lung cancer (NSCLC), a prospective non-randomized trial showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback